cemdisiran
Cemdisiran in aHUS
Phase 2 small_molecule terminated
Quick answer
cemdisiran for Atypical Hemolytic Uremic Syndrome is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Atypical Hemolytic Uremic Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated